Projected impact of anti‐obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity
Authors' conclusion
Increasing utilization of anti-obesity pharmacotherapy may widen relative disparities in obesity, particularly if utilization is unequal. Advocacy for equitable access is needed to minimize worsening of obesity-related disparities.
Study context
- Population
- American adolescents aged 12–17 years, National Health and Nutrition Examination Survey cycles 2011 through pre-pandemic 2020representing 26,247,384 adolescents
- Participants
- 4,442 adolescents
- Exposure
- Projected obesity prevalence with 10%–100% utilization of anti-obesity pharmacotherapy
- Outcome
- Projected obesity prevalence, stratified by race and ethnicity
Methodological detailssimulation using nationally representative survey data, stratified by race and ethnicity
- Simulation using nationally representative survey data
- Stratified by race and ethnicity
Main finding
As reported in the abstract
Projected overall obesity prevalence
Overall obesity prevalence decreased with 100% utilization, from
22.2% to 8.4%
Disparities increased relative to Non-Hispanic White youth; prevalence among Non-Hispanic Black and Mexican American youth higher, ranging from
40%-60% higher to 90%-120% higher, respectively
Observational data: associations, not effects.
Original publication
Projected impact of anti‐obesity pharmacotherapy use on racial and ethnic disparities in adolescent obesity. Pediatr Obes. Published 6 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →